Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.76 |
| ▸ | ACHE | P22303 | 14/20 | 0.69 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625938 | 1.00 | EPHX2 (0.76) | EPHX2ACHEPLA2G2AADRA1AEPHX1 | |
| SCHEMBL19400416 | 1.00 | EPHX2 (0.76) | EPHX2ACHEPLA2G2AADRA1AEPHX1 | |
| SCHEMBL3629434 | 1.00 | EPHX2 (0.76) | EPHX2ACHEPLA2G2AADRA1AEPHX1 | |
| SCHEMBL19400387 | 1.00 | EPHX2 (0.76) | EPHX2ACHEPLA2G2AADRA1AEPHX1 | |
| SCHEMBL19400357 | 1.00 | EPHX2 (0.76) | EPHX2ACHEPLA2G2AADRA1AEPHX1 | |
| SCHEMBL19400363 | 1.00 | EPHX2 (0.76) | EPHX2ACHEPLA2G2AADRA1AEPHX1 | |
| SCHEMBL3655324 | 0.98 | EPHX2 (0.74) | EPHX2ACHEPLA2G2A | |
| SCHEMBL8920145 | 0.95 | EPHX2 (0.84) | EPHX2ACHEPLA2G2AEPHX1 | |
| SCHEMBL9190902 | 0.95 | EPHX2 (0.84) | EPHX2ACHEPLA2G2AEPHX1 | |
| SCHEMBL9830221 | 0.95 | EPHX2 (0.84) | EPHX2ACHEPLA2G2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-2063002-B1 | Method for depositing and patterning carbon nanotubes using chemical self-assembly process | SAMSUNG ELECTRONICS CO LTD (KR) | 2011-11-23 | — | — | EP | disclosed |
| EP-2268604-A1 | THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE | Retrotope, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2234982-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1455007-B1 | Method for depositing and patterning carbon nanotubes using chemical self-assembly process | SAMSUNG ELECTRONICS CO LTD (KR) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009080523-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2063002-A2 | Method for depositing and patterning carbon nanotubes using chemical self-assembly process | Samsung Electronics Co., Ltd. (KR) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| CN-1284720-C | Lamination and picture composition method utilizing chemical self-assembly process | SAMSUNG ELECTRONICS CO LTD (KR) | 2006-11-15 | — | — | CN | disclosed |
| WO-2004067516-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040142285-A1 | Method for laminating and patterning carbon nanotubes using chemical self-assembly process | SAMSUNG ELECTRONICS CO., LTD. | 2004-07-22 | — | — | US | disclosed |
| CN-1500715-A | Lamination and picture composition method utilizing chemical self-assembly process | ���ǵ�����ʽ���� | 2004-06-02 | — | — | CN | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| EP-0703905-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | EPHX2 4515/4885ACHE 4751/4885PLA2G2A 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.